Literature DB >> 15138316

Use of diuretics in cardiovascular disease: (2) hypertension.

S U Shah1, S Anjum, W A Littler.   

Abstract

Hypertension is a common condition associated with increased mortality and multiple morbidities. Evidence based management of hypertension is known to improve both the short term and the long term outcomes in patients with this condition. There are several general measures and pharmacological agents that are known to treat hypertension adequately. Diuretics, in particular low dose thiazide and thiazide-like diuretics, are widely used in the treatment of hypertension. They have excellent outcome data and high safety and low side effects profiles. In this article, the physiology, pharmacological actions, side effects, and outcome data of the use of diuretics in hypertension are reviewed. In addition, the effective use of diuretics in the management of hypertension is discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15138316      PMCID: PMC1742995          DOI: 10.1136/pgmj.2003.010843

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  25 in total

1.  Correlation of coronary angiography with "tombstoning" electrocardiographic pattern in patients after acute myocardial infarction.

Authors:  X H Guo; Y G Yap; L J Chen; J Huang; A J Camm
Journal:  Clin Cardiol       Date:  2000-05       Impact factor: 2.882

Review 2.  Diuretics as a basis of antihypertensive therapy. An overview.

Authors:  N M Kaplan
Journal:  Drugs       Date:  2000       Impact factor: 9.546

3.  An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy.

Authors:  J F Burris; M R Weir; S Oparil; M Weber; W J Cady; W H Stewart
Journal:  JAMA       Date:  1990-03-16       Impact factor: 56.272

4.  Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

Authors:  B Dahlöf; L H Lindholm; L Hansson; B Scherstén; T Ekbom; P O Wester
Journal:  Lancet       Date:  1991-11-23       Impact factor: 79.321

5.  Polymorphous ventricular tachycardia early after acute myocardial infarction.

Authors:  Y Birnbaum; S Sclarovsky; R Ben-Ami; E Rechavia; B Strasberg; J Kusniec; A Mager; J Sulkes
Journal:  Am J Cardiol       Date:  1993-03-15       Impact factor: 2.778

Review 6.  Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease.

Authors:  P R Hebert; M Moser; J Mayer; R J Glynn; C H Hennekens
Journal:  Arch Intern Med       Date:  1993-03-08

7.  Sodium restriction in hypertensive patients treated with a converting enzyme inhibitor and a thiazide.

Authors:  D R Singer; N D Markandu; A L Sugden; M A Miller; G A MacGregor
Journal:  Hypertension       Date:  1991-06       Impact factor: 10.190

8.  Selective pulmonary and venous smooth muscle relaxation by furosemide: a comparison with morphine.

Authors:  S Greenberg; C McGowan; J Xie; W R Summer
Journal:  J Pharmacol Exp Ther       Date:  1994-09       Impact factor: 4.030

9.  A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide.

Authors:  W H Frishman; B S Bryzinski; L R Coulson; V L DeQuattro; N D Vlachakis; W J Mroczek; G Dukart; J D Goldberg; D Alemayehu; K Koury
Journal:  Arch Intern Med       Date:  1994-07-11

Review 10.  Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

Authors:  R Collins; R Peto; S MacMahon; P Hebert; N H Fiebach; K A Eberlein; J Godwin; N Qizilbash; J O Taylor; C H Hennekens
Journal:  Lancet       Date:  1990-04-07       Impact factor: 79.321

View more
  2 in total

Review 1.  Potential medicinal benefits of Cosmos caudatus (Ulam Raja): A scoping review.

Authors:  Shi-Hui Cheng; Mohd Yusof Barakatun-Nisak; Joseph Anthony; Amin Ismail
Journal:  J Res Med Sci       Date:  2015-10       Impact factor: 1.852

2.  Nanoparticle-Mediated Angiotensin-(1-9) Drug Delivery for the Treatment of Cardiac Hypertrophy.

Authors:  Sabrina Sepúlveda-Rivas; Matías S Leal; Zully Pedrozo; Marcelo J Kogan; María Paz Ocaranza; Javier O Morales
Journal:  Pharmaceutics       Date:  2021-06-01       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.